Clinical Effect of Syp. Kankasava in Patients With COVID-19: A Preliminary Observational Study
Abstract
COVID-19 commonly presents with cough and respiratory distress. Syp. Kankasava is a classical Ayurvedic fermented formulation traditionally used for respiratory complaints. However, direct clinical evidence for its use in COVID-19 remains limited, and it should not replace evidence-based COVID-19 treatment or oxygen support. Objective: To describe the change in cough, breathlessness, and recorded oxygen-related clinical score among COVID-19 patients treated with Syp. Kankasava.
Keywords
Kankasava; Kanakasava; COVID-19; cough; dyspnoea; Ayurveda; observational study; respiratory symptoms.
References
1.World Health Organization. Clinical management
of COVID-19: living guideline. Geneva: WHO;
updated 2025.
2.World Health Organization. WHO guidelines on
good herbal processing practices for herbal medicines.
Geneva: WHO.
3.Ministry of AYUSH, Government of India. The
Ayurvedic Formulary of India. New Delhi: Ministry
of AYUSH.
4.Planet Ayurveda. Kanakasava: ingredients,
indications and dosage. Available online; accessed
October 7, 2026.
5.Status of evidence on efficacy and safety of Indian
traditional medicine (AYUSH) for COVID-19: a
qualitative review and evidence-map synthesis.
Systematic Reviews. 2026.
6.Ayurvedic formulations: potential COVID-19
therapeutics? Journal of Ayurveda and Integrative
Medicine. 2022.